Septerna (NASDAQ:SEPN) Announces Discontinuation of SEP-786 Phase 1 Clinical Trial
Septerna, a clinical-stage biotechnology company, recently made public its decision to halt the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786, an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism. The company decided to discontinue the trial following two unanticipated severe events of elevated unconjugated bilirubin […]
Septerna, a clinical-stage biotechnology company, recently made public its decision to halt the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786, an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism. The company decided to discontinue the trial following two unanticipated severe events of elevated unconjugated bilirubin […]
